Seres Therapeutics (MCRB) Price & Analysis

Compare

1,075 Followers

MCRB Stock Chart & Stats

$18.52

>-$0.01(-0.25%)

At close: Jan 08 4:00 PM EST

$18.52

>-$0.01(-0.25%)

Day’s Range― - ―

52-Week Range$6.53 - $29.98

Previous CloseN/A

Volume457.00K

Average Volume (3M)231.61K

Market Cap

$160.21M

Enterprise Value$206.38M

Total Cash (Recent Filing)$47.64M

Total Debt (Recent Filing)$85.25M

Price to Earnings (P/E)29.2

Beta1.46

Next Earnings

Mar 10, 2026

EPS Estimate

-2.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.94

Shares Outstanding9,046,519

10 Day Avg. Volume489,438

30 Day Avg. Volume231,606

Financial Highlights & Ratios

PEG Ratio-189.72

Price to Book (P/B)187.37

Price to Sales (P/S)0.00

P/FCF Ratio-17.34

Enterprise Value/Market Cap1.29

Enterprise Value/Revenue587.97

Enterprise Value/Gross Profit-11.73

Enterprise Value/Ebitda21.34

Forecast

1Y Price Target

$22.00

Price Target Upside18.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.35

Revenue Forecast (FY)$7.83M

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe recently announced reduction in force and receipt of a $3.6M grant from CARB-X will give Seres sufficient lead time for securing essential funding.

Regulatory ProgressSeres received constructive feedback from FDA regarding study design for their phase 2 trial of SER-155 in allo-HSCT.

Strategic PartnershipsThe company announced a new investigator-led study at Memorial Sloan Kettering Cancer Center in NYC investigating SER-155 in immune checkpoint related enterocolitis (irEC).

Bears Say

Capital RequirementsMCRB requires additional capital to support the study and stated that partnership discussions are advancing, highlighting a need for financial resources.

Funding ChallengesSeres is still working towards partnering to secure funding for the phase 2 study of SER-155 in allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Seres Therapeutics News

Seres Therapeutics reports Q3 EPS 94c vs ($6.69) last year

Reports Q3 revenue $351,000, consensus $5.88M. “Following constructive feedback from the FDA, we are working to finalize our...

17d ago

MCRB

Seres Therapeutics receives award of up to $3.6M from CARB-X

Seres Therapeutics (MCRB) will provide up to $3.6 million in additional non-dilutive funding to the Company. The grant...

24d ago

MCRB

Seres Therapeutics Reports Positive Q3 2025 Results

Seres Therapeutics Inc. ( ($MCRB) ) has released its Q3 earnings. Here is a breakdown of the information...

16d ago

MCRB

Seres Therapeutics Reports Positive Q3 Earnings Call

Seres Therapeutics Inc. (($MCRB)) has held its Q3 earnings call. Read on for the main highlights of the...

17d ago

MCRB

Seres Therapeutics Reports Q3 Results and Business Updates

An update from Seres Therapeutics ( ($MCRB) ) is now available. On November 5, 2025, Seres Therapeutics reported...

17d ago

MCRB

MCRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Seres Therapeutics Inc. (MCRB) is scheduled to report 3rd quarter earnings on 11/05/2025, before the market opens. Regarding...

19d ago

MCRB

Seres Therapeutics to present new post hoc data from SER-155 Phase 1b trial

Seres Therapeutics (MCRB) announced that new post hoc data from its SER-155 Phase 1b trial will be featured...

1M ago

MCRB

Seres Therapeutics Cuts Costs to Extend Cash Runway

Seres Therapeutics ( ($MCRB) ) has issued an update. On September 23, 2025, Seres Therapeutics announced a reduction...

2M ago

MCRB

Seres Therapeutics price target raised to $22 from $14 at Canaccord

Canaccord raised the firm’s price target on Seres Therapeutics (MCRB) to $22 from $14 and keeps a Buy...

2M ago

MCRB

Seres Therapeutics announces further constructive feedback from FDA on SER-155

Seres Therapeutics (MCRB) announced receipt of additional constructive feedback from the U.S. Food and Drug Administration, FDA, on...

2M ago

MCRB

Seres Therapeutics’ Earnings Call: Progress Amid Challenges

Seres Therapeutics Inc. (($MCRB)) has held its Q2 earnings call. Read on for the main highlights of the...

4M ago

MCRB

Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Seres Therapeutics, with...

4M ago

MCRB

Seres Therapeutics Reports Q2 2025 Financial Results

Seres Therapeutics Inc. ( ($MCRB) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

MCRB

Seres Therapeutics Reports Q2 Results and Leadership Change

Seres Therapeutics ( ($MCRB) ) has shared an announcement. On August 6, 2025, Seres Therapeutics reported its second...

4M ago

MCRB

MCRB FAQ

What was Seres Therapeutics Inc.’s price range in the past 12 months?

Seres Therapeutics Inc. lowest stock price was $6.53 and its highest was $29.98 in the past 12 months.

What is Seres Therapeutics Inc.’s market cap?

Seres Therapeutics Inc.’s market cap is $160.21M.

When is Seres Therapeutics Inc.’s upcoming earnings report date?

Seres Therapeutics Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 108 days.

How were Seres Therapeutics Inc.’s earnings last quarter?

Seres Therapeutics Inc. released its earnings results on Nov 05, 2025. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.457 by $0.483.

Is Seres Therapeutics Inc. overvalued?

According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Seres Therapeutics Inc. pay dividends?

Seres Therapeutics Inc. does not currently pay dividends.

What is Seres Therapeutics Inc.’s EPS estimate?

Seres Therapeutics Inc.’s EPS estimate is -2.11.

How many shares outstanding does Seres Therapeutics Inc. have?

Seres Therapeutics Inc. has 9,046,519 shares outstanding.

What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?

Seres Therapeutics Inc. reported an EPS of $0.94 in its last earnings report, beating expectations of $0.457. Following the earnings report the stock price went down -7.636%.

Which hedge fund is a major shareholder of Seres Therapeutics Inc.?

Currently, no hedge funds are holding shares in MCRB

Seres Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

15.95%

Trailing 12-Months

Asset Growth

-19.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Seres Therapeutics Inc.

Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome therapeutics. The company operates in the healthcare sector and is dedicated to creating innovative treatments for diseases by harnessing the therapeutic potential of the human microbiome. Seres Therapeutics' core products include a pipeline of biologically-derived drugs aimed at treating diseases such as Clostridium difficile infection (CDI) and other conditions linked to dysbiosis of the gut microbiota.

Seres Therapeutics (MCRB) Earnings & Revenues

Historic Earnings Reports

MCRB Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.View all MCRB earnings summaries

MCRB Stock 12 Month Forecast

Average Price Target

$22.00

▲(18.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","26":"$26","12.5":"$12.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12.5,17,21.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.54,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >